-
1.发明申请BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOF 审中-公开结合蛋白质，包括抗体，抗体衍生物和抗体片段，特别是CD154及其用途
公开(公告)号：WO2008118356A3
公开(公告)日：2008-11-20
申请号：PCT/US2008003735
申请日：2008-03-21
Applicant: BIOGEN IDEC INC , UCB PHARMA SA , BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
Inventor： BURKLY LINDA C , FERRANT-ORGETTAS JANINE L , GARBER ELLEN A , HSU YEN-MING , SU LIHE , TAYLOR FREDERICK R , ADAMS RALPH , BROWN DEREK THOMAS , POPPLEWELL ANDREW GEORGE , ROBINSON MARTYN KIM , SHOCK ANTHONY , TYSON KERRY LOUISE
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12N15/63
CPC classification number: C07K16/2875 , A61K39/3955 , A61K45/06 , A61K2039/505 , C07K2317/24 , C07K2317/34 , C07K2317/40 , C07K2317/52 , C07K2317/55 , C07K2317/71 , C07K2317/734 , C07K2317/76 , C07K2317/92
Abstract: This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable heavy chain sequence according to SEQ ID NO: 1 and comprising a variable light chain sequence according to SEQ ID NO: 2 specifically binds. CD154 binding proteins of this invention may elicit reduced effector function relative to a second anti-CD154 antibody. CD154 binding proteins of this invention are useful in diagnostic and therapeutic methods, such as in the treatment and prevention of diseases including those that involve undesirable immune responses that are mediated by CD154-CD40 interactions.
Abstract translation: 本发明提供特异性结合CD154（CD40L）蛋白的结合蛋白，包括抗体，抗体衍生物和抗体片段。 本发明还提供了嵌合，人源化或完全人抗体，抗体衍生物或抗体片段，其特异性结合包含根据SEQ ID NO：1的可变重链序列的人源化Fab片段的表位，并包含可变轻链序列 根据SEQ ID NO：2特异性结合。 本发明的CD154结合蛋白可以引起相对于第二抗-CD154抗体降低的效应子功能。 本发明的CD154结合蛋白可用于诊断和治疗方法，例如治疗和预防包括由CD154-CD40相互作用介导的不良免疫应答的疾病。
-
公开(公告)号：CA2872326C
公开(公告)日：2020-10-13
申请号：CA2872326
申请日：2013-05-13
Applicant: UCB PHARMA SA
Inventor： FINNEY HELENE MARGARET , LAWSON ALASTAIR DAVID GRIFFITHS , SHAW STEVAN GRAHAM , SMITH BRYAN JOHN , TYSON KERRY LOUISE , KEVORKIAN LARA , MEIER CHRISTOPH , SARKAR KAUSHIK , ATHERFOLD PAUL ALAN
IPC: C07K16/28 , A61K39/395 , C12N15/13 , C12P21/08
Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
-
公开(公告)号：CA2754539C
公开(公告)日：2017-09-12
申请号：CA2754539
申请日：2010-03-10
Applicant: UCB PHARMA SA
Inventor： GOZZARD NEIL , LAWSON ALASTAIR DAVID GRIFFITHS , LIGHTWOOD DANIEL JOHN , PALFRAMAN ROGER THOMAS , SMITH BRYAN JOHN , TYSON KERRY LOUISE
IPC: C07K16/24 , A61K39/395 , A61P11/06 , C07K16/46 , C12N15/13
Abstract: Antibody molecules having specificity for antigenic determinants of human IL-13, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.
-
公开(公告)号：MA37619B1
公开(公告)日：2017-07-31
申请号：MA37619
申请日：2013-05-13
Applicant: UCB PHARMA SA
Inventor： FINNEY HELENE MARGARET , LAWSON ALASTAIR DAVID GRIFFITHS , SHAW STEVAN GRAHAM , SMITH BRYAN JOHN , TYSON KERRY LOUISE , KEVORKIAN LARA , MEIER CHRISTOPH , SARKAR KAUSHIK , ATHERFOLD PAUL ALAN
Abstract: L'invention concerne des anticorps spécifiques de fcrn, des formulations les comprenant, l'utilisation de chacun en thérapie, des procédés d'expression et facultativement de formulations dudit anticorps, de l'adn codant pour les anticorps et des hôtes comprenant ledit adn.
-
公开(公告)号：MA37619A1
公开(公告)日：2016-01-29
申请号：MA37619
申请日：2013-05-13
Applicant: UCB PHARMA SA
Inventor： FINNEY HELENE MARGARET , LAWSON ALASTAIR DAVID GRIFFITHS , SHAW STEVAN GRAHAM , SMITH BRYAN JOHN , TYSON KERRY LOUISE , KEVORKIAN LARA , MEIER CHRISTOPH , SARKAR KAUSHIK , ATHERFOLD PAUL ALAN
Abstract: L'invention concerne des anticorps spécifiques de fcrn, des formulations les comprenant, l'utilisation de chacun en thérapie, des procédés d'expression et facultativement de formulations dudit anticorps, de l'adn codant pour les anticorps et des hôtes comprenant ledit adn..
-
Patent Agency Ranking
公开(公告)号：CL2014003110A1
公开(公告)日：2015-06-19
申请号：CL2014003110
申请日：2014-11-14
Applicant: UCB PHARMA SA
-
公开(公告)号：CO7151521A2
公开(公告)日：2014-12-29
申请号：CO14272175
申请日：2014-12-11
Applicant: UCB PHARMA SA
Inventor： FINNEY HELENE MARGARET , LAWSON ALASTAIR DAVID GRIFFITHS , SHAW STEVAN GRAHAM , SMITH BRYAN JOHN , TYSON KERRY LOUISE , KEVORKIAN LARA , MEIER CHRISTOPH , SARKAR KAUSHIK , ATHERFOLD PAUL ALAN
Abstract: ver pestaña anexos
-
公开(公告)号：PH12014502274B1
公开(公告)日：2014-12-10
申请号：PH12014502274
申请日：2014-10-09
Applicant: UCB PHARMA SA
Inventor： FINNEY HELENE MARGARET , LAWSON ALASTAIR DAVID GRIFFITHS , SHAW STEVAN GRAHAM , SMITH BRYAN JOHN , TYSON KERRY LOUISE , KEVORKIAN LARA , MEIER CHRISTOPH , SARKAR KAUSHIK , ATHERFOLD PAUL ALAN
Abstract: The disclosure relates to antibodies specific to FcRn, formulations comprising the same, use of each in therapy, processes for expressing and optionally formulating said antibody, DNA encoding the antibodies and hosts comprising said DNA.
-
公开(公告)号：MX2014012890A
公开(公告)日：2014-11-14
申请号：MX2014012890
申请日：2013-05-13
Applicant: UCB PHARMA SA
Inventor： TYSON KERRY LOUISE , FINNEY HELENE MARGARET , LAWSON ALASTAIR DAVID GRIFFITHS , SHAW STEVAN GRAHAM , SMITH BRYAN JOHN , KEVORKIAN LARA , MEIER CHRISTOPH , SARKAR KAUSHIK , ATHERFOLD PAUL ALAN
Abstract: La descripción se refiere a los anticuerpos específicos para FcRn, a las formulaciones que comprenden los mismos, el uso de cada uno en terapia, los procesos para expresar y para formar opcionalmente el anticuerpo, el ADN que codifica para los anticuerpos y hospederos que comprenden el ADN.
-
10.发明专利
公开(公告)号：PE15472014A1
公开(公告)日：2014-10-25
申请号：PE0003532014
申请日：2012-09-10
Applicant: UCB PHARMA SA
Inventor： HUMPHREYS DAVID PAUL , LIGHTWOOD DANIEL JOHN , TYSON KERRY LOUISE , KNIGHT DAVID EDWARD ORMONDE , HERVE KARINE JEANNINE MADELEINE , COMPSON JOANNE ELIZABETH , PAGE MATTHEW JON TIMOTHY , PAYNE ANDREW CHARLES , FISHER NICOLA LOUISE , MACKENZIE BRENDON , COX MATTHEW
CPC classification number: C07K16/1282 , A61K39/40 , A61K45/06 , A61K2039/505 , A61K2039/507 , A61K2039/545 , C07K2317/76 , C07K2317/92 , C07K2317/94 , G01N33/56911 , G01N33/573 , G01N33/6854 , G01N2333/91097
Abstract: SE REFIERE A UN ANTICUERPO MONOCLONAL ESPECIFICO FRENTE AL ANTIGENO TCDA O TCDB, QUE COMPRENDE UNA CADENA PESADA EN EL DOMINIO VARIABLE QUE TIENE UNA CDR QUE COMPRENDE LA SECUENCIA DADA EN SEQ ID NO: 44 PARA CDR-H1, UNA CDR EN SEQ ID NO: 45 PARA CDR-H2 Y UNA CDR EN SEQ ID NO: 46 PARA CDR-H3; Y UNA CADENA LIGERA EN EL DOMINIO VARIABLE QUE TIENE UNA CDR QUE COMPRENDE LA SECUENCIA DADA EN SEQ ID NO: 41 PARA CDR-L1, UNA CDR EN SEQ ID NO: 42 PARA CDR-L2 Y UNA CDR EN SEQ ID NO:43 PARA CDR-L3. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE ES UTIL PARA EL TRATAMIENTO O LA PROFILAXIS DE LA INFECCION POR CLOSTRIDIUM DIFFICILE.
-
-
-
-
-
-
-
-
-
Search Results
59
records
(took 0.026 seconds)
